Rumors of an acquisition swirled last month before being proven as fact in December.
News & Analysis: Tesaro
A big day for potential mergers and acquisitions helped power some of these stocks higher.
GlaxoSmithKline's first major pharma acquisition in years isn't a hit with shareholders.
This isn't the first time this biotech has explored a sale, but conditions are a little different now.
Investors continue to digest data from the biotech's competitors.
Good news for a rival drug translates to bad news for Tesaro.
The company is advancing a research program that it hopes will improve outcomes for patients with non-small cell lung cancer.
Is there a light at the end of the tunnel?
Find out how poor earnings hit some of these companies hard.
The commercial-stage biotech has offered up a less-than-optimistic outlook.